Resonancia magnética dinámica de mama: estudio comparativo de gadobutrol y Gd-DTPA

Escribano, Fernanda; Sentís, Melcior; Oliva, Joan Carles; Tortajada, Lidia; Villajos, Maite; Martín, Adrián; Ganau, Sergi

doi:10.1016/j.rx.2017.10.010

Cited by 4 publications

(2 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the other study ( n = 52), gadobutrol-enhanced MRI was noninferior to gadobenate meglumine-enhanced MRI for breast lesion detection and sensitivity in lesion characterization [ 35 ]. A retrospective study of 400 patients with histologically-confirmed breast cancer provides further support for the diagnostic efficacy of gadobutrol-enhanced MRI in detecting breast lesions [ 37 ].…”

Section: Diagnostic Efficacy Of Gadobutrolmentioning

confidence: 99%

Gadobutrol: A Review in Contrast-Enhanced MRI and MRA

Scott¹

2018

Clin Drug Investig

View full text Add to dashboard Cite

Intravenous gadobutrol [Gadovist™ (EU); Gadavist® (USA)] is a second-generation, extracellular non-ionic macrocyclic gadolinium-based contrast agent (GBCA) that is approved for use in paediatric (including term neonates) and adult patients undergoing diagnostic contrast-enhanced (CE) MRI for visualization of pathological lesions in all body regions or for CE MRA to evaluate perfusion and flow-related abnormalities. Its unique physicochemical profile, including its high thermostability and proton relaxation times, means that gadobutrol is formulated at twice the gadolinium ion concentration of other GBCAs, resulting in a narrower bolus and consequently, improved dynamic image enhancement. Based on >  20 years of experience in the clinical trial and real-world settings (>  50 million doses) and its low risk for developing nephrogenic systemic fibrosis (NSF), gadobutrol represents an effective and safe diagnostic GBCA for use in CE MRI and MRA to visualize pathological lesions and vascular perfusion and flow-related abnormalities in all body regions in a broad spectrum of patients, including term neonates and other paediatric patients, young and elderly adult patients, and those with moderate or severe renal or hepatic impairment or cardiovascular (CV) disease.

show abstract

Section: Diagnostic Efficacy Of Gadobutrolmentioning

confidence: 99%

Gadobutrol: A Review in Contrast-Enhanced MRI and MRA

Scott¹

2018

Clin Drug Investig

View full text Add to dashboard Cite

show abstract

“…They evaluated 400 patients with breast cancer. Two-hundred patients underwent dynamic contrast-enhanced MRI (DCE-MRI) with the gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA) contrast (Magnevist®) and the other 200 with gadobutrol (Gadovist®) [14]. The differences between these two agents are summarized in Table 3.…”

Section: Contrast Agent In Enhanced Breast Mrimentioning

confidence: 99%

Magnetic Resonance Imaging Features in Different Types of Invasive Breast Cancer: A Systematic Review of the Literature

Alaref¹,

Hassan²,

Kandel³

et al. 2021

Cureus

View full text Add to dashboard Cite

Breast cancer is the most common malignancy affecting women worldwide, and early diagnosis of breast cancer is the key to its successful and effective treatment. Traditional imaging techniques such as mammography and ultrasound are used to detect and configure breast abnormalities; unfortunately, these modalities have low sensitivity and specificity, particularly in young patients with dense breast tissue, breast implants, or post-surgical scar/architecture distortions. Therefore, breast magnetic resonance imaging (MRI) has been superior in the characterization and detection of breast cancer, especially that with invasive features. This review article explores the importance of breast MRI in the early detection of invasive breast cancer versus traditional tools, including mammography and ultrasound, while also analyzing the use of MRI as a screening tool for high-risk women. We will also discuss the different MRI features for invasive ductal carcinoma and lobular carcinoma and the role of breast MRI in the detection of ductal carcinoma in situ with a focus on the utilization of new techniques, including MR spectroscopy and diffusion-weighted imaging.

show abstract